4//SEC Filing
Epstein Marie 4
Accession 0000899243-20-035279
CIK 0001445283other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 7:20 PM ET
Size
9.1 KB
Accession
0000899243-20-035279
Insider Transaction Report
Form 4
Epstein Marie
Principal Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-12-22+38,373→ 38,373 totalExercise: $8.16Exp: 2028-12-03→ Common Stock (38,373 underlying) - Award
Stock Option (Right to Buy)
2020-12-22+4,216→ 4,216 totalExercise: $8.16Exp: 2030-02-17→ Common Stock (4,216 underlying)
Footnotes (5)
- [F1]On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity.
- [F2]25% of the shares subject to the option vested on July 31, 2019. The remaining 75% vest in equal monthly installments over the subsequent three years.
- [F3]Received in the Merger in exchange for a stock option to acquire 182,000 shares of Yumanity, Inc. common stock for $1.72 per share.
- [F4]25% of the shares subject to the option vest on February 18, 2021. The remaining 75% vest in equal monthly installments over the subsequent three years.
- [F5]Received in the Merger in exchange for a stock option to acquire 20,000 shares of Yumanity, Inc. common stock for $1.72 per share.
Documents
Issuer
YUMANITY THERAPEUTICS, INC.
CIK 0001445283
Entity typeother
Related Parties
1- filerCIK 0001834469
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 7:20 PM ET
- Size
- 9.1 KB